Merck’s Taxpayer-Subsidized COVID Pill Linked to New Virus Mutations, Study Finds

By Michael Nevradakis, Ph.D. | The Defender | February 3, 2023 Merck’s oral antiviral pill for COVID-19, molnupiravir — marketed under the name Lagevrio — may be fueling the development of new and potentially deadly variants of COVID-19, according to the authors of a new preprint study. The study, released Jan. 27 by a team of U.S. and U.K […]